Nuvalent announced the initiation of the Phase 2 portion of ARROS-1, its Phase 1/2 clinical trial of NVL-520 for patients with ROS1-positive non-small cell lung cancer, or NSCLC, and other solid tumors, following alignment with the FDA on a recommended Phase 2 dose of 100 mg daily.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NUVL:
- Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
- DraftKings upgraded, Home Depot downgraded: Wall Street’s top analyst calls
- Nuvalent initiated with a Market Perform at SVB Securities
- Tesla downgraded, Netflix upgraded: Wall Street’s top analyst calls
- Nuvalent initiated with a Buy at Guggenheim
